Last updated on July 2019

Prostate Cancer Outcomes: An International Registry to Improve Outcomes in Men With Advanced Prostate Cancer (IRONMAN)


Brief description of study

Our intent is to establish the International Registry to Improve Outcomes in Men with Advanced Prostate Cancer (IRONMAN) as a prospective, international cohort of minimum 5,000 men with advanced cancer, including men with mHSPC and M0/M1 CRPC. The goal is to establish a population-based registry and recruit patients across academic and community practices from Australia, Brazil, Canada, Ireland, Sweden, Switzerland, the United Kingdom (UK), and the US. Target accrual number and number of participating sites are subject to change based on accrual, funding, and interest in participation by other international sites. This cohort study will facilitate a better understanding of the variation in care and treatment of advanced prostate cancer across countries and across academia and community based practices.

Detailed data will be collected from patients at study enrollment and then during follow-up, for a minimum of three years. Patients will be followed prospectively for overall survival, clinically significant adverse events, comorbidities, changes in cancer treatments, and PROMs.

PROMs questionnaires will be collected at enrollment, every three months for the first and second year then every six months.

Physician Questionnaires will be collected from all participating sites at patient enrollment, time of first change in treatment and/or one year follow-up, at each subsequent change of treatment, and discontinuation of treatment.

As such, this registry will help identify the treatment sequences or combinations that optimize overall survival and PROMs for men with mHSPC and M0/M1 CRPC. By collecting blood at enrollment, time of first change in treatment and/or one year follow-up (plasma, cell free DNA, buffy coat / RNA), this registry will further identify and validate molecular phenotypes of disease that predict response and resistance to specific therapeutics. Additionally, every effort will be made to collect blood specimen at each subsequent change in treatment. When feasible, existing tumor tissue may be collected for correlation with described blood based studies. All samples will be used for future research. This cohort study will provide the research community with a unique biorepository to identify biomarkers of treatment response and resistance.

Clinical Study Identifier: NCT03151629

Find a site near you

Start Over

University of Chicago

Chicago, IL United States
  Connect »

Tulane University

New Orleans, LA United States
  Connect »

University of Michigan

Ann Arbor, MI United States
  Connect »

Karmanos Cancer Institute

Detroit, MI United States
  Connect »

Weill Cornell Medical Center

New York, NY United States
  Connect »

Duke University

Durham, NC United States
  Connect »

Thomas Jefferson University

Philadelphia, PA United States
  Connect »

Baylor College of Medicine

Houston, TX United States
  Connect »

University of Virginia

Charlottesville, VA United States
  Connect »

Redland Hospital

Cleveland, Australia
  Connect »

BC Cancer Agency

Vancouver, BC Canada
  Connect »

Kantonsspital St. Gallen

Saint Gallen, Switzerland
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.